TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05693077

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 10E4 NTCD spores
Description: in capsule for oral ingestion.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 10E4 NTCD spores
Description: in capsule for oral ingestion.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 10E4 NTCD spores
Description: in capsule for oral ingestion.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 10E4 NTCD spores
Description: in capsule for oral ingestion.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 10E7 NTCD spores
Description: in capsule for oral ingestion.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 10E7 NTCD spores
Description: in capsule for oral ingestion.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 10E7 NTCD spores
Description: in capsule for oral ingestion.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 10E7 NTCD spores
Description: in capsule for oral ingestion.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 10E7 NTCD spores
Description: in capsule for oral ingestion.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: in capsule for oral ingestion.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: placebo
Description: in capsule for oral ingestion.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: in capsule for oral ingestion.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: placebo
Description: in capsule for oral ingestion.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: in capsule for oral ingestion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vancomycin Oral Capsule
Description: 4 times a day 250mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vancomycin Oral Capsule
Description: 4 times a day 250mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vancomycin Oral Capsule
Description: 4 times a day 250mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vancomycin Oral Capsule
Description: 4 times a day 250mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vancomycin Oral Capsule
Description: 4 times a day 250mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vancomycin Oral Capsule
Description: 4 times a day 250mg
Study: NCT06225440

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Levagen+® Palmitoylethanolamide (PEA)
Description: Participants were instructed to swallow 2 opaque capsules (Levagen+® - 90% of PEA) with water daily at the same time of the day for 6 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants were instructed to swallow 2 opaque capsules (Microcrystalline Cellulose) with water daily at the same time of the day for 6 weeks.
Study: NCT05613049

Intervention type: OTHER
Description: If the CE is high, antibiotics will be given to the patients as usual practice in hospitals.
Study: NCT04857567

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TSC program (Three Self-Commitment program)
Description: 1. Self-Competence program~   - A program for residents who experience exhaustion due to the spirit of volunteerism and high expectations of therapeutic competency in the case of experiencing a decrease in personal achievement.~2. Self-Care program~   - A program to help individuals who experience dehumanization due to emotional suppression and develop exhaustion in the process of suppressing emotions to protect themselves from excessive feelings of compassion experienced in the medical scene~3. Self-Compassion program - A program for residents who experience emotional burnout and exhaustion due to pressure of failure because medical professionals should be competent and excellent
Study: NCT06509620

Intervention type: OTHER
Intervention: Fatigue severity scale
Description: fatigue severity scale is a unidimensional, nine-item questionnaire capturing information on the impact and severity of fatigue. Participants rated the 9-items on a 7-point, Likert-type scale with anchors of strongly disagree (1) and strongly agree (7) based on the previous week. The overall score is an average of the individual item scores and can range between 1 and 7.

Intervention type: OTHER
Intervention: Fatigue severity scale
Description: fatigue severity scale is a unidimensional, nine-item questionnaire capturing information on the impact and severity of fatigue. Participants rated the 9-items on a 7-point, Likert-type scale with anchors of strongly disagree (1) and strongly agree (7) based on the previous week. The overall score is an average of the individual item scores and can range between 1 and 7.
Study: NCT05389995

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Potassium citrate
Description: 7 days potassium citrate followed by 24 hour urine collection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Crystal light
Description: 7 days crystal light followed by 24 hour urine collection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Potassium citrate + crystal light
Description: 7 days potassium citrate + crystal light followed by 24 hour urine collection
Study: NCT05329168

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tonabacase (LSVT-1701)
Description: 4.5 or 6.0 mg/kg IV once daily for 4 days
Study: NCT05696132

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Betadine
Description: Nasal decolonization with betadine gel
Study: NCT06031636

Intervention type: DRUG
Intervention: Oncolytic Adenovirus H101
Description: The oncolytic virus(H101) is administered by intratumoral injection or intrapleural injection on days 1-3 of the first medication cycle. PD-1 inhibitor is administered on days 4 or 5, with one infusion per cycle. The treatment regimen consists of 2-4 cycles

Intervention type: DRUG
Intervention: Programmed death receptor-1 inhibitor
Description: The oncolytic virus(H101) is administered by intratumoral injection or intrapleural injection on days 1-3 of the first medication cycle. PD-1 inhibitor is administered on days 4 or 5, with one infusion per cycle. The treatment regimen consists of 2-4 cycles
Study: NCT06177951

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NICU Discharge Passport
Description: The NICU discharge passport contains a discharge checklist highlighting important go-to information for infants (feeding plan, medications, pharmacy information, pediatrician, and follow ups post-discharge). It also provides key anticipatory guidance for newborns.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NICU Discharge Passport
Description: The NICU discharge passport contains a discharge checklist highlighting important go-to information for infants (feeding plan, medications, pharmacy information, pediatrician, and follow ups post-discharge). It also provides key anticipatory guidance for newborns.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NICU Infant Care Class
Description: The class will be provided once or twice weekly to eligible study participants. It will be conducted in a small group format. Class teachers will focus on providing key anticipatory guidance to aid in the transition home during the first month of life . Topics related to infant care will be discussed, including feeding, elimination, skincare, hygiene, soothing, development, and when to see a doctor/emergencies.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NICU Infant Care Class
Description: The class will be provided once or twice weekly to eligible study participants. It will be conducted in a small group format. Class teachers will focus on providing key anticipatory guidance to aid in the transition home during the first month of life . Topics related to infant care will be discussed, including feeding, elimination, skincare, hygiene, soothing, development, and when to see a doctor/emergencies.
Study: NCT06398509

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: The control intervention includes brief health education and coaching sessions just after well child visits in the first two years of life (total of 7 sessions), 2 text messages per week for the primary caregiver and up to two additional family members, and environmental prompts that support healthy behaviors. The control intervention focuses on home safety, home management of common childhood illnesses, and promotion of language development.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Futuros Fuertes 2.0
Description: The Futuros Fuertes 2.0 intervention includes brief health education and coaching sessions just after well child visits in the first two years of life (total of 7 sessions), 2 text messages per week for the primary caregiver and up to two additional family members, and environmental prompts that support healthy behaviors. The Futuros Fuertes 2.0 intervention focuses on optimal infant feeding, screen time, and sleep practices.
Study: NCT04591379

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Influenza Vaccines
Description: Intratumoral application of an unattenuated influenza vaccine
Study: NCT05011877

Intervention type: DEVICE
Intervention: High-flow nasal cannula therapy
Description: High-flow nasal cannula therapy (HFNC) (from 25 - 60 L/min based on patient's tolerance) will be used in 21 participants during one additional sleep study to investigate its acute impact on reducing sleep abnormalities. Inspired fraction of oxygen will be titrated to maintain patient SpO2 similar to the levels during standard oxygen therapy.

Intervention type: DEVICE
Intervention: High-flow nasal cannula therapy
Description: High-flow nasal cannula therapy (HFNC) (from 25 - 60 L/min based on patient's tolerance) will be used in 21 participants during one additional sleep study to investigate its acute impact on reducing sleep abnormalities. Inspired fraction of oxygen will be titrated to maintain patient SpO2 similar to the levels during standard oxygen therapy.
Study: NCT05327751

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celecoxib 200mg
Description: 200 mg of oral celecoxib twice daily for 14 days of the 3-week cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine-based chemotherapy
Description: Capecitabine-based chemotherapy

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Capecitabine-based chemotherapy
Description: Capecitabine-based chemotherapy
Study: NCT05527899

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Zinc gluconate
Description: 30 and 60 mg/d of zinc gluconate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zinc gluconate
Description: 30 and 60 mg/d of zinc gluconate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zinc gluconate
Description: 30 and 60 mg/d of zinc gluconate
Study: NCT05541913

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tele nursing
Description: The intervention group in the study will be the parents of children who received routine care in the surgical service and who received tele-nursing service, who had undergone circumcision operation.After the admission of the child in the service, the Beck Anxiety Scale will be applied to measure the anxiety levels of the parents at the first hospitalization. After the routine discharge training in the service, the Beck Anxiety Scale and Health Care Satisfaction Scale will be applied to the parents again. Then, the parents will be called on the 1st postoperative day and training will be provided. On the postoperative 2nd, 3rd and 4th days, counseling will be provided. on the postoperative 4th day Parents will be asked to fill in the Beck Anxiety sScale and Health Care Satisfaction scale.
Study: NCT06323967

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Large unconditional cash transfers plus voluntary peer support.
Description: These participants will receive monthly cash transfers of $1,500 ($750 twice per month) via debit card for 24 months and can elect to participate in peer support services plus usual care from shelter staff.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nominal cash transfers
Description: These participants will receive monthly cash transfers of $50 via debit card for 24 months plus usual care from shelter staff.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Passive comparison group
Description: These families will receive usual care from shelter staff. They will be followed anonymously in administrative records only.
Study: NCT06161337

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Meals
Description: Each subject will participate in 4 visits with a 1-week washout period in between visits.~Each visit will be either a morning or evening consumption of either a standardized mixed meal of containing 600 calories (standard control) or 2400 calories (overeating meal) - meals will have the same nutrient composition.
Study: NCT06059599

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: active informed consent
Description: new preoperative information method, based on multimedia tools and on the objective control of understanding by the patient candidate for vertebral or urological surgery.
Study: NCT05334043

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CuminUP30
Description: 7 capsules, 500 mg / capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CuminUP30
Description: 7 capsules, 500 mg / capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Curcumin capsules
Description: 5 capsules, 450 mg / capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Curcumin capsules
Description: 5 capsules, 450 mg / capsule
Study: NCT05624190

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Human tenecteplase Tissue-type Plasminogen Activator (rhTNK-tPA)
Description: The administration of rhTNK-tPA will be infused constant and slowly over 15min (0.125 mg/kg, Max 12.5mg) through a microcatheter.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best Medical Management
Description: Best Medical Management

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Medical Management
Description: Best Medical Management
Study: NCT04781270

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFOXIRI regimen
Description: oxaliplatin 85 mg/m2, irinotecan 165 mg/m2, and folinic acid 400 mg/m2 followed by 5-fluorouracil 2400mg/m2 as a 46-hour continuous infusion on day 1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mFOLFOX regimen
Description: oxaliplatin 85 mg/m2, and folinic acid 400 mg/m2 followed by bolus 5-fluorouracil 400 mg/m2 and 5-fluorouracil 2400mg/m2 as a 46-hour continuous infusion on day 1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: 5 mg/kg on day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 5 mg/kg on day 1
Study: NCT05752526

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac 1%
Description: vaginal hydrogel containing 1% Diclofenac

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac 3%
Description: vaginal hydrogel containing 3% Diclofenac

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: vaginal hydrogel, no active ingredient
Study: NCT05306743

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CONQUEST Quality Improvement Program
Description: CONQUEST supports primary healthcare professionals to diagnose, assess, and optimize the management of their patients with modifiable high-risk COPD, through the promotion of guideline-based care. CONQUEST will promote management according to four Quality Standards for the care of modifiable high-risk COPD patients. The Quality Standards can be summarized as the timely and appropriate: Identification of high-risk patient groups for assessment; Assessment of disease and quantification of future risk; Non-pharmacological and pharmacological intervention; Follow-up. CONQUEST program will promote adherence to these standards through the use of electronic medical record -based algorithms for the identification of high-risk patients and clinical decision support resources. All decisions regarding patient management are made entirely at the discretion of the clinicians and patients who together negotiate the preferred course of action during consultations.

Intervention type: OTHER
Group type: OTHER
Intervention: CONQUEST Quality Improvement Program
Description: CONQUEST supports primary healthcare professionals to diagnose, assess, and optimize the management of their patients with modifiable high-risk COPD, through the promotion of guideline-based care. CONQUEST will promote management according to four Quality Standards for the care of modifiable high-risk COPD patients. The Quality Standards can be summarized as the timely and appropriate: Identification of high-risk patient groups for assessment; Assessment of disease and quantification of future risk; Non-pharmacological and pharmacological intervention; Follow-up. CONQUEST program will promote adherence to these standards through the use of electronic medical record -based algorithms for the identification of high-risk patients and clinical decision support resources. All decisions regarding patient management are made entirely at the discretion of the clinicians and patients who together negotiate the preferred course of action during consultations.
Study: NCT04916951

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Description: oral one-time dose of amoxicillin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cephalexin
Description: oral one-time dose of cephalexin
Study: NCT05301998

Intervention type: OTHER
Group type: OTHER
Intervention: Skin and thickness measurement/breast MRI
Description: Patient will be installed in dorsal decubitus position. Measurements will be performed at 3 sites on one breast: at the areola, above the areola and below. Measurements will be performed by a single gynecologist using a cutometer provided by TIMC-IMAG laboratory of Grenoble. Three measurements will be performed at each site. Duration of measurements will be approximately 15 minutes.~Measurement of skin thickness will be performed using an ultrasound device available in obstetrics/gynecology consultation department. The measurement will be performed at 3 sites. The duration of the measurements will be of approximately 10 minutes.~Among the 200 patients, 10 patients who should benefit from a breast MRI as part of their follow-up, will have a breast MRI in 3 different positions: prone (standard protocol) and two additional acquisitions (as part of the research) in dorsal and right lateral decubitus. This examination will be scheduled in the senology department of the Lapeyronie Hospital
Study: NCT04258683

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Patients not progressing after 2 cycles of CyBorD treatment and achieving less than VGPR by IMWG criteria will be screened to receive pembrolizumab intravenously at 200mg at day 1 of every 3-week cycle for 8 cycles (24 weeks) starting Cycle 4 of CyBorD. CyBorD will be discontinued after 24 weeks and pembrolizumab will be administered as a single agent at the same dose for an additional 27 cycles (81 weeks).
Study: NCT05233709

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: FeSO4 + OTf
Description: OTf (apo ovotransferrin) + FeSO4

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: FeSO4 + Lf
Description: Lf (lactoferrin) + FeSO4

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: FeSO4
Description: Ferrous sulfate
Study: NCT05115292

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BJ-005
Description: dosed with intravenous infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BJ-005
Description: dosed with intravenous infusion
Study: NCT05360628

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-0120 in combination with Allopurinol
Description: noted above

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-0120 in combination with Allopurinol
Description: noted above
Study: NCT05772611

Intervention type: BIOLOGICAL
Intervention: Genetic and immunology tests
Description: This is a non-interventional study involving clinical data and biological samples (blood, DNA, CSF, cells). Clinical data are collected for the center and samples are already stored in biobank repositories and collected as part of good clinical practice in the diagnostic process of patients with suspected autoimmune encephalitis, meaning that the standard diagnostic and therapeutic approaches will not be altered in the selected study population. Patients have already gave explicit written consent for biological specimens sampling and storage at the Centre de Ressources Biologiques des Hospices Civils de Lyon (CRB-HCL) (including tissue, cells or biological fluids) and genetic analysis for research purposes.

Intervention type: BIOLOGICAL
Intervention: Genetic and immunology tests
Description: This is a non-interventional study involving clinical data and biological samples (blood, DNA, CSF, cells). Clinical data are collected for the center and samples are already stored in biobank repositories and collected as part of good clinical practice in the diagnostic process of patients with suspected autoimmune encephalitis, meaning that the standard diagnostic and therapeutic approaches will not be altered in the selected study population. Patients have already gave explicit written consent for biological specimens sampling and storage at the Centre de Ressources Biologiques des Hospices Civils de Lyon (CRB-HCL) (including tissue, cells or biological fluids) and genetic analysis for research purposes.

Intervention type: BIOLOGICAL
Intervention: Genetic and immunology tests
Description: This is a non-interventional study involving clinical data and biological samples (blood, DNA, CSF, cells). Clinical data are collected for the center and samples are already stored in biobank repositories and collected as part of good clinical practice in the diagnostic process of patients with suspected autoimmune encephalitis, meaning that the standard diagnostic and therapeutic approaches will not be altered in the selected study population. Patients have already gave explicit written consent for biological specimens sampling and storage at the Centre de Ressources Biologiques des Hospices Civils de Lyon (CRB-HCL) (including tissue, cells or biological fluids) and genetic analysis for research purposes.